Company: Harbor BioSciences, Inc, HRBR
Price: 0.29
Change: 38.10%
Volume: 656,500
Harbor BioSciences, Inc., a development stage pharmaceutical company, engages in the discovery, development, and commercialization of products for the treatment of diseases related to aging. The company focuses on developing a series of steroid hormone analogs that are derived from the human adrenal metabolome. Its clinical drug development candidates include APOPTONE (HE3235), a compound that is in Phase I/IIa clinical trials for late-stage prostate cancer; and TRIOLEX (HE3286), a compound that is in early Phase II clinical trials for the treatment of type 2 diabetes, as well as in Phase II clinical trials for the treatment of ulcerative colitis and rheumatoid arthritis diseases. The company was formerly known as Hollis-Eden Pharmaceuticals Inc. and changed its name to Harbor BioSciences, Inc. in February 2010. Harbor BioSciences was founded in 1992 and is headquartered in San Diego, California.
The Views and Opinions Expressed by the author are his or her opinions only and do not necessarily reflect those of this Web-Site or its agents, affiliates, officers, directors, staff, or contractors. The author at the time of this article did not own any shares or receive any consideration financial or otherwise from any company or person mentioned or referred to in the article.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
No comments:
Post a Comment